DOI QR코드

DOI QR Code

Hepatitis B Virus Gene Mutations and Hepatocarcinogenesis

  • Liang, Tao (Center of Infectious Diseases, West China Hospital of Sichuan University) ;
  • Chen, En-Qiang (Center of Infectious Diseases, West China Hospital of Sichuan University) ;
  • Tang, Hong (Center of Infectious Diseases, West China Hospital of Sichuan University)
  • Published : 2013.08.30

Abstract

Chronic hepatitis B virus (HBV) infection has long been the most common cause of hepatocellular carcinoma (HCC). However, some aspects of the pathogenesis of HBV infection and genesis of hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC) are still inconclusive. An increasing number of published studies indicate that hepatitis B virus mutations are associated with risk of HCC. These variations include, in particular, mutations in ORF S,C,X gene regions. This mini-review summarizes results of clinical studies and molecular mechanisms on the possible relations of HBV mutations with the development of hepatocellular carcinoma.

Keywords

Hepatocellular carcinoma;hepatitis B virus;gene mutations

References

  1. Abe K, Thung SN, Wu HC, et al (2009). Pre-S2 deletion mutants of hepatitis B virus could have an important role in hepatocarcinogenesis in Asian children. Cancer Sci, 100, 2249-54. https://doi.org/10.1111/j.1349-7006.2009.01309.x
  2. Arzumanyan A, Reis HM,Feitelson MA (2013). Pathogenic mechanisms in HBV- and HCV-associated hepatocellular carcinoma. Nat Rev Cancer, 13, 123-35. https://doi.org/10.1038/nrc3449
  3. Bouchard MJ,Schneider RJ (2004). The enigmatic X gene of hepatitis B virus. J Virol, 78, 12725-34. https://doi.org/10.1128/JVI.78.23.12725-12734.2004
  4. Chan HL, Hui AY, Wong ML, et al (2004). Genotype C hepatitis B virus infection is associated with an increased risk of hepatocellular carcinoma. Gut, 53, 1494-8. https://doi.org/10.1136/gut.2003.033324
  5. Chen BF, Liu CJ, Jow GM, et al (2006). High prevalence and mapping of pre-S deletion in hepatitis B virus carriers with progressive liver diseases. Gastroenterology, 130, 1153-68. https://doi.org/10.1053/j.gastro.2006.01.011
  6. Choi CS, Cho EY, Park R, et al (2009). X gene mutations in hepatitis B patients with cirrhosis, with and without hepatocellular carcinoma. J Med Virol, 81, 1721-5. https://doi.org/10.1002/jmv.21591
  7. Dong Q, Chan HL, Liu Z, et al (2008). A1762T/G1764A mutations of hepatitis B virus, associated with the increased risk of hepatocellular carcinoma, reduce basal core promoter activities. Biochem Biophys Res Commun, 374, 773-6. https://doi.org/10.1016/j.bbrc.2008.07.115
  8. Du H, Li T, Zhang HY, et al (2007). Correlation of hepatitis B virus (HBV). genotypes and mutations in basal core promoter/precore with clinical features of chronic HBV infection. Liver Int, 27, 240-6. https://doi.org/10.1111/j.1478-3231.2006.01400.x
  9. Fan W, Shi B, Wei H, et al (2011). Comparison of hepatitis B X gene mutation between patients with hepatocellular carcinoma and patients with chronic hepatitis B. Virus Genes, 42, 162-70. https://doi.org/10.1007/s11262-010-0557-5
  10. Fang ZL, Sabin CA, Dong BQ, et al (2008). HBV A1762T, G1764A mutations are a valuable biomarker for identifying a subset of male HBsAg carriers at extremely high risk of hepatocellular carcinoma: a prospective study. Am J Gastroenterol, 103, 2254-62. https://doi.org/10.1111/j.1572-0241.2008.01974.x
  11. Fang ZL, Sabin CA, Dong BQ, et al (2008). Hepatitis B virus pre-S deletion mutations are a risk factor for hepatocellular carcinoma: a matched nested case-control study. J Gen Virol, 89, 2882-90. https://doi.org/10.1099/vir.0.2008/002824-0
  12. Forner A, Llovet JM,Bruix J (2012). Hepatocellular carcinoma. Lancet, 379, 1245-55. https://doi.org/10.1016/S0140-6736(11)61347-0
  13. Hannoun C, Horal P,Lindh M (2000). Long-term mutation rates in the hepatitis B virus genome. J Gen Virol, 81, 75-83.
  14. Heo NY, Lee HC, Park YK, et al (2013). Lack of association between hepatitis B virus pre-S mutations and recurrence after surgical resection in hepatocellular carcinoma. J Med Virol, 85, 589-96. https://doi.org/10.1002/jmv.23502
  15. Hosaka T, Suzuki F, Kobayashi M, et al (2010). Development of HCC in patients receiving adefovir dipivoxil for lamivudine-resistant hepatitis B virus mutants. Hepatol Res, 40, 145-52. https://doi.org/10.1111/j.1872-034X.2009.00582.x
  16. Hung JH, Teng YN, Wang LH, et al (2011). Induction of Bcl-2 expression by hepatitis B virus pre-S2 mutant large surface protein resistance to 5-fluorouracil treatment in Huh-7 cells. PLoS One, 6, e28977. https://doi.org/10.1371/journal.pone.0028977
  17. Hussain Z, Jung HS, Ryu DK,Ryu WS (2009). Genetic dissection of naturally occurring basal core promoter mutations of hepatitis B virus reveals a silent phenotype in the overlapping X gene. J Gen Virol, 90, 2272-81. https://doi.org/10.1099/vir.0.010421-0
  18. Ishikawa T (2010). Clinical features of hepatitis B virus-related hepatocellular carcinoma. World J Gastroenterol, 16, 2463-7. https://doi.org/10.3748/wjg.v16.i20.2463
  19. Jammeh S, Tavner F, Watson R, et al (2008). Effect of basal core promoter and pre-core mutations on hepatitis B virus replication. J Gen Virol, 89, 901-9. https://doi.org/10.1099/vir.0.83468-0
  20. Kim HJ, Park JH, Jee Y, et al (2008). Hepatitis B virus X mutations occurring naturally associated with clinical severity of liver disease among Korean patients with chronic genotype C infection. J Med Virol, 80, 1337-43. https://doi.org/10.1002/jmv.21219
  21. Kuang SY, Jackson PE, Wang JB, et al (2004). Specific mutations of hepatitis B virus in plasma predict liver cancer development. Proc Natl Acad Sci U S A, 101, 3575-80. https://doi.org/10.1073/pnas.0308232100
  22. Kusakabe A, Tanaka Y, Inoue M, et al (2011). A population-based cohort study for the risk factors of HCC among hepatitis B virus mono-infected subjects in Japan. J Gastroenterol, 46, 117-24. https://doi.org/10.1007/s00535-010-0307-4
  23. Lai MW,Yeh CT (2008). The oncogenic potential of hepatitis B virus rtA181T/ surface truncation mutant. Antivir Ther, 13, 875-9.
  24. Lauder IJ, Lin HJ, Lau JY, et al (1993). The variability of the hepatitis B virus genome: statistical analysis and biological implications. Mol Biol Evol, 10, 457-70.
  25. Lee JH, Han KH, Lee JM, et al (2011). Impact of hepatitis B virus (HBV). x gene mutations on hepatocellular carcinoma development in chronic HBV infection. Clin Vaccine Immunol, 18, 914-21. https://doi.org/10.1128/CVI.00474-10
  26. Liao Y, Hu X, Chen J, et al (2012). Precore mutation of hepatitis B virus may contribute to hepatocellular carcinoma risk: evidence from an updated meta-analysis. PLoS One, 7, e38394. https://doi.org/10.1371/journal.pone.0038394
  27. Lin CL, Liu CH, Chen W, et al (2007). Association of pre-S deletion mutant of hepatitis B virus with risk of hepatocellular carcinoma. J Gastroenterol Hepatol, 22, 1098-103. https://doi.org/10.1111/j.1440-1746.2006.04515.x
  28. Liu S, Xie J, Yin J, et al (2011). A matched case-control study of hepatitis B virus mutations in the preS and core promoter regions associated independently with hepatocellular carcinoma. J Med Virol, 83, 45-53. https://doi.org/10.1002/jmv.21829
  29. Liu S, Zhang H, Gu C, et al (2009). Associations between hepatitis B virus mutations and the risk of hepatocellular carcinoma: a meta-analysis. J Natl Cancer Inst, 101, 1066-82. https://doi.org/10.1093/jnci/djp180
  30. Ma NF, Lau SH, Hu L, et al (2008). COOH-terminal truncated HBV X protein plays key role in hepatocarcinogenesis. Clin Cancer Res, 14, 5061-8. https://doi.org/10.1158/1078-0432.CCR-07-5082
  31. Malik A, Singhal DK, Albanyan A, et al (2012). Hepatitis B virus gene mutations in liver diseases: a report from New Delhi. PLoS One, 7, e39028. https://doi.org/10.1371/journal.pone.0039028
  32. Mathews P, Lee D, Chung YH, et al (2012). Effects of genomic changes in hepatitis B virus on postoperative recurrence and survival in patients with hepatocellular carcinoma. Ann Surg Oncol, 20, 1216-22.
  33. Michel ML,Tiollais P (1987). Structure and expression of the hepatitis B virus genome. Hepatology, 7, S61-3. https://doi.org/10.1002/hep.1840070711
  34. Minemura M, Shimizu Y, Hirano K, et al (2005). Functional analysis of transactivation by mutants of hepatitis B virus X gene in human hepatocellular carcinoma. Oncol Rep, 14, 495-9.
  35. Mun HS, Lee SA, Kim H, et al (2011). Novel F141L pre-S2 mutation in hepatitis B virus increases the risk of hepatocellular carcinoma in patients with chronic genotype C infections. J Virol, 85, 123-32. https://doi.org/10.1128/JVI.01524-10
  36. Murakami S (2001). Hepatitis B virus X protein: a multifunctional viral regulator. J Gastroenterol, 36, 651-60. https://doi.org/10.1007/s005350170027
  37. Muroyama R, Kato N, Yoshida H, et al (2006). Nucleotide change of codon 38 in the X gene of hepatitis B virus genotype C is associated with an increased risk of hepatocellular carcinoma. J Hepatol, 45, 805-12. https://doi.org/10.1016/j.jhep.2006.07.025
  38. Ng SA,Lee C (2011). Hepatitis B virus X gene and hepatocarcinogenesis. J Gastroenterol, 46, 974-90. https://doi.org/10.1007/s00535-011-0415-9
  39. Ni Y, Sonnabend J, Seitz S,Urban S (2010). The pre-s2 domain of the hepatitis B virus is dispensable for infectivity but serves a spacer function for L-protein-connected virus assembly. J Virol, 84, 3879-88. https://doi.org/10.1128/JVI.02528-09
  40. Park NH,Chung YH (2007). [Molecular mechanisms of hepatitis B virus-associated hepatocellular carcinoma]. Korean J Hepatol, 13, 320-40. https://doi.org/10.3350/kjhep.2007.13.3.320
  41. Schmitt S, Glebe D, Alving K, et al (1999). Analysis of the pre-S2 N- and O-linked glycans of the M surface protein from human hepatitis B virus. J Biol Chem, 274, 11945-57. https://doi.org/10.1074/jbc.274.17.11945
  42. Seeger C,Mason WS (2000). Hepatitis B Virus Biology. Microbiol Mol Biol Rev, 64, 51-68. https://doi.org/10.1128/MMBR.64.1.51-68.2000
  43. Shi HP, Zhang J, Shang XC,Xie XY (2013). Hepatitis B virus gene C1653T polymorphism mutation and hepatocellular carcinoma risk: an updated meta-analysis. Asian Pac J Cancer Prev, 14, 1043-7. https://doi.org/10.7314/APJCP.2013.14.2.1043
  44. Tanaka Y, Mukaide M, Orito E, et al (2006). Specific mutations in enhancer II/core promoter of hepatitis B virus subgenotypes C1/C2 increase the risk of hepatocellular carcinoma. J Hepatol, 45, 646-53. https://doi.org/10.1016/j.jhep.2006.06.018
  45. Tang H, Oishi N, Kaneko S,Murakami S (2006). Molecular functions and biological roles of hepatitis B virus x protein. Cancer Sci, 97, 977-83. https://doi.org/10.1111/j.1349-7006.2006.00299.x
  46. Tatsukawa M, Takaki A, Shiraha H, et al (2011). Hepatitis B virus core promoter mutations G1613A and C1653T are significantly associated with hepatocellular carcinoma in genotype C HBV-infected patients. BMC Cancer, 11, 458. https://doi.org/10.1186/1471-2407-11-458
  47. Tian Y, Xu Y, Zhang Z, et al (2007). The amino Acid residues at positions 120 to 123 are crucial for the antigenicity of hepatitis B surface antigen. J Clin Microbiol, 45, 2971-8. https://doi.org/10.1128/JCM.00508-07
  48. Tong MJ, Blatt LM, Kao JH, et al (2007). Basal core promoter T1762/A1764 and precore A1896 gene mutations in hepatitis B surface antigen-positive hepatocellular carcinoma: a comparison with chronic carriers. Liver Int, 27, 1356-63. https://doi.org/10.1111/j.1478-3231.2007.01585.x
  49. Tsai WL, Lo GH, Hsu PI, et al (2008). Role of genotype and precore/basal core promoter mutations of hepatitis B virus in patients with chronic hepatitis B with acute exacerbation. Scand J Gastroenterol, 43, 196-201. https://doi.org/10.1080/00365520701745693
  50. Tsukuma H, Tanaka H, Ajiki W,Oshima A (2005). Liver cancer and its prevention. Asian Pac J Cancer Prev, 6, 244-50.
  51. Tu H, Bonura C, Giannini C, et al (2001). Biological impact of natural COOH-terminal deletions of hepatitis B virus X protein in hepatocellular carcinoma tissues. Cancer Res, 61, 7803-10.
  52. Villet S, Pichoud C, Billioud G, et al (2008). Impact of hepatitis B virus rtA181V/T mutants on hepatitis B treatment failure. J Hepatol, 48, 747-55. https://doi.org/10.1016/j.jhep.2008.01.027
  53. Wang HC, Chang WT, Chang WW, et al (2005). Hepatitis B virus pre-S2 mutant upregulates cyclin A expression and induces nodular proliferation of hepatocytes. Hepatology, 41, 761-70. https://doi.org/10.1002/hep.20615
  54. Xu L, Qian G, Tang L, et al (2010). Genetic variations of hepatitis B virus and serum aflatoxin-lysine adduct on high risk of hepatocellular carcinoma in Southern Guangxi, China. J Hepatol, 53, 671-6. https://doi.org/10.1016/j.jhep.2010.04.032
  55. Yang HI, Yeh SH, Chen PJ, et al (2008). Associations between hepatitis B virus genotype and mutants and the risk of hepatocellular carcinoma. J Natl Cancer Inst, 100, 1134-43. https://doi.org/10.1093/jnci/djn243
  56. Yeh CT, Chen T, Hsu CW, et al (2011). Emergence of the rtA181T/sW172* mutant increased the risk of hepatoma occurrence in patients with lamivudine-resistant chronic hepatitis B. BMC Cancer, 11, 398. https://doi.org/10.1186/1471-2407-11-398
  57. Yeh CT, Chien RN, Chu CM,Liaw YF (2000). Clearance of the original hepatitis B virus YMDD-motif mutants with emergence of distinct lamivudine-resistant mutants during prolonged lamivudine therapy. Hepatology, 31, 1318-26. https://doi.org/10.1053/jhep.2000.7296
  58. Yeh CT, Shen CH, Tai DI, et al (2000). Identification and characterization of a prevalent hepatitis B virus X protein mutant in Taiwanese patients with hepatocellular carcinoma. Oncogene, 19, 5213-20. https://doi.org/10.1038/sj.onc.1203903
  59. Yeung P, Wong DK, Lai CL, et al (2011). Association of hepatitis B virus pre-S deletions with the development of hepatocellular carcinoma in chronic hepatitis B. J Infect Dis, 203, 646-54. https://doi.org/10.1093/infdis/jiq096
  60. Yin J, Xie J, Liu S, et al (2011). Association between the various mutations in viral core promoter region to different stages of hepatitis B, ranging of asymptomatic carrier state to hepatocellular carcinoma. Am J Gastroenterol, 106, 81-92. https://doi.org/10.1038/ajg.2010.399
  61. Yuan JM, Ambinder A, Fan Y, et al (2009). Prospective evaluation of hepatitis B 1762(T)./1764(A). mutations on hepatocellular carcinoma development in Shanghai, China. Cancer Epidemiol Biomarkers Prev, 18, 590-4. https://doi.org/10.1158/1055-9965.EPI-08-0966
  62. Yuen MF, Tanaka Y, Shinkai N, et al (2008). Risk for hepatocellular carcinoma with respect to hepatitis B virus genotypes B/C, specific mutations of enhancer II/core promoter/precore regions and HBV DNA levels. Gut, 57, 98-102.
  63. Zhu ZZ, Wang D, Cong WM, et al (2012). Sex-related differences in DNA copy number alterations in hepatitis B virus-associated hepatocellular carcinoma. Asian Pac J Cancer Prev, 13, 225-9. https://doi.org/10.7314/APJCP.2012.13.1.225

Cited by

  1. Epidemiology and Survival of Hepatocellular Carcinoma in the Central Region of Thailand vol.15, pp.8, 2014, https://doi.org/10.7314/APJCP.2014.15.8.3567
  2. Schedule-Dependent Effects of Kappa-Selenocarrageenan in Combination with Epirubicin on Hepatocellular Carcinoma vol.15, pp.8, 2014, https://doi.org/10.7314/APJCP.2014.15.8.3651
  3. Association between underexpression of microrna-203 and clinicopathological significance in hepatocellular carcinoma tissues vol.15, pp.1, 2015, https://doi.org/10.1186/s12935-015-0214-0
  4. Patients with Spontaneously Ruptured Hepatocellular Carcinoma Benefit from Staged Surgical Resection after Successful Transarterial Embolization vol.16, pp.1, 2015, https://doi.org/10.7314/APJCP.2015.16.1.315
  5. CYP2C19 Genotype Could be a Predictive Factor for Aggressive Manifestations of Hepatocellular Carcinoma Related with Chronic Hepatitis B Infection in Thailand vol.16, pp.8, 2015, https://doi.org/10.7314/APJCP.2015.16.8.3253
  6. A prominent role of Hepatitis D Virus in liver cancers documented in Central Africa vol.16, pp.1, 2016, https://doi.org/10.1186/s12879-016-1992-2
  7. miRNA-708 functions as a tumour suppressor in hepatocellular carcinoma by targeting SMAD3 vol.14, pp.2, 2017, https://doi.org/10.3892/ol.2017.6429
  8. Comprehensive review of Hepatitis B Virus-associated hepatocellular carcinoma research through text mining and big data analytics pp.14647931, 2018, https://doi.org/10.1111/brv.12457
  9. Applications of next-generation sequencing analysis for the detection of hepatocellular carcinoma-associated hepatitis B virus mutations vol.25, pp.1, 2018, https://doi.org/10.1186/s12929-018-0442-4